Sino Biopharmaceutical Hepatitis B Drug Meets Primary Goal of Phase 2 Study

MT Newswires Live

01/27

Sino Biopharmaceutical (HKG:1177) said a mid-stage trial of its TQA3605 tablets for the treatment of hepatitis B met its primary goal, according to a Hong Kong bourse filing Tuesday.

Results showed the medicine, when combined with antiviral drugs known as nucleos(t)ide analogues, helped kept the disease at bay.

Specifically, after 24 weeks of treatment, HBV-infected adults who received the company's medicine achieved HBV DNA levels below the lower limit of quantification when compared to nucleos(t)ide analogues alone.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2606734204"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606734204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606734204?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606734204","market":"sg","top_or_hot":-1,"title":"Sino Biopharmaceutical Hepatitis B Drug Meets Primary Goal of Phase 2 Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> (HKG:1177) said a mid-stage trial of its TQA3605 tablets for the treatment of hepatitis B met its primary goal, according to a Hong Kong bourse filing Tuesday.</p><p>Results showed the medicine, when combined with antiviral drugs known as nucleos(t)ide analogues, helped kept the disease at bay.</p><p>Specifically, after 24 weeks of treatment, HBV-infected adults who received the company's medicine achieved HBV DNA levels below the lower limit of quantification when compared to nucleos(t)ide analogues alone.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Hepatitis B Drug Meets Primary Goal of Phase 2 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Hepatitis B Drug Meets Primary Goal of Phase 2 Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-27 17:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> (HKG:1177) said a mid-stage trial of its TQA3605 tablets for the treatment of hepatitis B met its primary goal, according to a Hong Kong bourse filing Tuesday.</p><p>Results showed the medicine, when combined with antiviral drugs known as nucleos(t)ide analogues, helped kept the disease at bay.</p><p>Specifically, after 24 weeks of treatment, HBV-infected adults who received the company's medicine achieved HBV DNA levels below the lower limit of quantification when compared to nucleos(t)ide analogues alone.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YT58.USD","symbol_name":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606734204","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606734204","pubTimestamp":1769504671,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical  said a mid-stage trial of its TQA3605 tablets for the treatment of hepatitis B met its primary goal, according to a Hong Kong bourse filing Tuesday.Results showed the medicine, when combined with antiviral drugs known as nucleoside analogues, helped kept the disease at bay.Specifically, after 24 weeks of treatment, HBV-infected adults who received the company's medicine achieved HBV DNA levels below the lower limit of quantification when compared to nucleoside analogues alone.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1589":"北水核心资产","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1515":"抗疫概念","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"中国生物制药乙肝药物达到2期研究主要目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"Sino Biopharmaceutical (HKG:1177) said a mid-stage trial of its TQA3605 tablets for the treatment of hepatitis B met its primary goal, according to a Hong Kong bourse filing Tuesday.Results showed the medicine, when combined with antiviral drugs known as nucleos(t)ide analogues, helped kept the disease at bay.Specifically, after 24 weeks of treatment, HBV-infected adults who received the company's medicine achieved HBV DNA levels below the lower limit of quantification when compared to nucleos(t)ide analogues alone.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}